Innovent Biologics, Inc. (6IB.F)

4.6800 0.0000 (0.00%) As of 09:59AM CEST. Market open.

Innovent Biologics, Inc.

168 Dongping Street
Suzhou Industrial Park
Suzhou 215123
China
86 512 6956 6088
https://www.innoventbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 4,872

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. De-Chao Yu Ph.D.	Co-Founder, Chairman & CEO	4.71M	N/A	1964
Mr. Hao Xi Ede	Executive Director & Fund Managing Partner	918.58k	N/A	1959
Dr. Yong Jun Liu M.D., Ph.D.	President	N/A	N/A	1969
Ms. Fei You	Chief Financial Officer	N/A	N/A	1979
Ms. Vivian Zhang	Chief People Officer & GM	N/A	N/A	N/A
Mr. Min Liu	Chief Commercial Officer	N/A	N/A	N/A
Mr. Dongming Wang	Senior Vice President	N/A	N/A	N/A
Mr. Blake Salisbury	Senior Vice President	N/A	N/A	N/A
Dr. Hui Zhou Ph.D.	Senior Vice President	N/A	N/A	N/A
Dr. Nageatte Ibrahim M.D.	Oncology Chief Medical Officer	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI-326, a fully-human BCMA CAR T-cell therapy; IBI-376, an oral inhibitor of PI3Kd; IBI-351, a KRASG12C inhibitor; IBI-344, a repressor of silencing 1/TRK tyrosine kinase inhibitor; IBI-126, an ADC targeting CEACAM5; IBI-306, a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting anti-IL-23. In addition, it develops IBI-110, a novel anti-LAG3 monoclonal antibody; IBI-939, a novel anti-TIGIT monoclonal antibody; IBI-310, an anti-CTLA-4 monoclonal antibody; IBI-323, a novel LAG3/PD-L1 bispecific antibody; IBI-363, a potential PD-1/IL-2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 monoclonal ADC; and IBI-302, a potential anti-VEGF/complement bispecific fusion protein. Further, the company develops IBI-128, a late-stage novel non-purine xanthine oxidase inhibitor; IBI-353, a potent and selective, nextgeneration PDE4 inhibitor; and IBI-311, a recombinant anti-IGF-1R monoclonal antibody. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.

Corporate Governance

Innovent Biologics, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 10. The pillar scores are Audit: 3; Board: 5; Shareholder Rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.